EPISODE · Apr 12, 2023 · 27 MIN
A Biopharma Downturn or Return to Trend
from The Bio Report · host Levine Media Group
In 2022, investment in biopharmaceutical companies, pipeline activity, and the launch of novel medicines all dropped from the previous year. A new report from IQVIA’s Institute for Human Data Sciences argues the downturn, after two record-setting years, is a post pandemic return to longer-term trends. We spoke to Murray Aitken, executive director of the IQVIA Institute for Human Data Science, about what happened to the biopharmaceutical sector in 2022, how to make sense of the data, and the shifting landscape in therapeutic and geographic investments.
Embed this episode
What this episode covers
Murray Aitken, executive director of the IQVIA Institute for Human Data Science, discusses his organization’s new report on what happened to the biopharmaceutical sector in 2022, how to make sense of the data, and the shifting landscape in therapeutic and geographic investments.
NOW PLAYING
A Biopharma Downturn or Return to Trend
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.